Essentamin Injection 5%

Adult dosage

Administer via intravenous drip at a maximum dose of 1.5 g per day for every kg of body weight as total amino acids (equivalent to 2100 mL for a 70 kg individual). The administration rate should be 1.7 to 2.1 mL per kg of body weight over 60 minutes (equivalent to 40 to 50 drops per minute for a 70 kg individual).

This medication must be used strictly according to the physician's instructions and should not be taken or administered arbitrarily. It should not be administered to patients with severely impaired kidney function or those with high blood urea nitrogen levels. Patients with amino acid metabolism disorders not associated with liver dysfunction should also avoid using this medication. It should not be administered to patients with impaired nitrogen utilization, cachexia, pulmonary edema, oliguria, or anuria. Patients with elevated serum sodium and chloride levels or those with alkalosis, as well as those with heart block or severe myasthenia gravis, should not use this medication. Caution should be exercised when administering it to patients who are overhydrated or have a history of myocardial infarction. It should be used with caution in patients with severe acidosis, congestive heart failure, severe heart failure, edema due to sodium retention, hyperkalemia, potassium retention, and impaired kidney function. While using this medication, rare allergic reactions such as skin rashes may occur, so it should be discontinued immediately if such symptoms appear. Gastrointestinal symptoms such as nausea or vomiting may also occasionally occur. Cardiac-related symptoms such as chest discomfort, palpitations, rapid pulse, and elevated blood pressure may also appear, requiring careful monitoring. Rapid infusion of large volumes may lead to metabolic acidosis. In addition, severe side effects such as chills, fever, headache, difficulty breathing, shock, bronchospasm, and urinary spasm may occur. If magnesium is included, symptoms of peripheral vasodilation may also occur. Metabolic complications such as metabolic acidosis, hypophosphatemia, alkalosis, hyperglycemia, diabetes, dehydration, rebound hypoglycemia, elevated liver enzymes, vitamin imbalances, electrolyte imbalances, and pediatric hyperammonemia may occur. Patients with decreased liver or kidney function may experience elevated blood urea nitrogen (BUN) levels. Severely impaired liver function patients may show serum amino acid imbalances or metabolic alkalosis, systemic nitrogen surplus, hyperammonemia, decreased consciousness, or coma. Periodic testing is necessary as serum ammonia levels may change depending on treatment effectiveness. When this medication is administered in large doses or used in conjunction with electrolyte-containing solutions, meticulous attention to electrolyte balance is essential. Overdosage may lead to metabolic alkalosis; therefore, solutions containing acetate ions should be used cautiously. In patients with histories of kidney, lung, or heart diseases, care should be taken to avoid excessive fluid administration. Diabetic patients should frequently monitor blood glucose levels while administering this medication. Patients with hyponatremia or liver and kidney dysfunction should have individualized dose adjustments and meticulous management of fluid and electrolyte status. This medication may reduce the effectiveness of certain antibiotics when used together; thus, it is essential to consult a physician or pharmacist regarding other medications used. Safety has not been established for pregnant women; therefore, it should only be administered when the benefits of treatment outweigh the risks. Pediatric patients may have immature liver function, so lower concentrations should ideally be used, and blood ammonia levels should be frequently monitored. Elderly patients may have decreased physiological functions; therefore, care should be taken to slow the administration rate and reduce the dosage. This medication contains electrolytes, and rapid infusion may cause chills or vomiting and lead to increased amino acid loss through the kidneys. When administering it, temperature should be adjusted to body temperature, and preparation and handling should be done in a sterile environment to reduce the risk of infection. Do not use if the solution is cloudy or discolored, and it should be used as quickly as possible after opening. Storage should be in a sealed container to prevent air or moisture ingress. The recommended storage temperature is between 1°C and 30°C at room temperature. This way, the drug's effectiveness can be maintained for a longer time.

Serious side effects

Severe allergic reactions (hives, severe swelling, etc.), respiratory problems (difficulty breathing, respiratory arrest, bronchial spasms), severe edema (systemic severe edema, elevated blood pressure accompanying), liver abnormalities (jaundice is not specified, but symptoms related to liver failure and renal failure are present), and serious neurological symptoms (sensory loss, coma)

Mild side effects

• Rash
• nausea
• vomiting
• chest discomfort
• palpitations
• rapid pulse (tachycardia)
• elevated blood pressure
• metabolic acidosis
• hypophosphatemia
• alkalosis

This medication should be stored in a sealed container to prevent air or moisture from entering. It is advisable to maintain a storage temperature between 1°C and 30°C at room temperature to keep the medication effective for a longer time.

Appearance

A colorless to pale yellow transparent injection solution in a plastic container for infusion.

Package unit

250 milliliters/box, 100 milliliters/box